Information Provided By: 
Fly News Breaks for September 26, 2016
AGN, SHPG
Sep 26, 2016 | 07:50 EDT
Leerink analyst Jason Gerberry remains optimistic that Shire's (SHPG) Xiidra launch will "significantly" expand the category for dry eye disease brands, while not meaningfully eroding Allergan's (AGN) Restasis market leading position. While it's still early in the launch of Xiidra and payer access remains a critical variable, the analyst does not anticipate access being a major barrier. Gerberry reiterates an Outperform rating on both Shire and Allergan's shares.
News For SHPG;AGN From the Last 2 Days
There are no results for your query SHPG;AGN
